28836 Federal Register / Vol. 87, No. 91 / Wednesday, May 11, 2022 / Notices 

the applicable factors listed in section 

306(c)(3) of the FD&C Act and 

determined that a 3-year debarment is 

appropriate. 

As a result of the foregoing findings, 

Dr. Massouh is debarred for 3 years from 

providing services in any capacity to a 

person with an approved or pending 

drug product application under sections 

505, 512, or 802 of the FD&C Act (21 

U.S.C. 355, 360b, or 382), or under 

section 351 of the Public Health Service 

Act (42 U.S.C. 262), effective (DATE of 

NOTICE), (see 21 U.S.C. 335a(c)(1)(B) 

and (c)(2)(A)(iii) and 21 U.S.C. 321(dd)). 

Any person with an approved or 

pending drug application who 

knowingly uses the services of Dr. 

Massouh, in any capacity during his 

debarment, will be subject to civil 

money penalties (section 307(a)(6) of the 

FD&C Act (21 U.S.C. 335b(a)(6))). If Dr. 

Massouh, during his period of 

debarment, provides services in any 

capacity to a person with an approved 

or pending drug product application, he 

will be subject to civil money penalties 

(section 307(a)(7) of the FD&C Act). In 

addition, FDA will not accept or review 

any abbreviated new drug applications 

submitted by or with the assistance of 

Dr. Massouh during his period of 

debarment (section 306(c)(1)(B) of the 

FD&C Act). 

Dated: April 21, 2022. 

Jacqueline A. O’Shaughnessy, 

Acting Chief Scientist. 

[FR Doc. 2022–10096 Filed 5–10–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Skeletal Biology Development and Disease 

Study Section. 

Date: June 1–3, 2022. 

Time: 10:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Aruna K. Behera, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4211, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

6809, beheraak@csr.nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Interdisciplinary Clinical Care in Specialty 

Care Settings Study Section. 

Date: June 2–3, 2022. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Abu Saleh Mohammad 

Abdullah, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 827–4043, 

abuabdullah.abdullah@nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Kidney, Nutrition, Obesity and Diabetes 

Study Section. 

Date: June 2–3, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Steven Michael Frenk, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3141, 

Bethesda, MD 20892, (301) 480–8665, 

frenksm@mail.nih.gov. 

Name of Committee: Risk, Prevention and 

Health Behavior Integrated Review Group; 

Addiction Risks and Mechanisms Study 

Section. 

Date: June 6–7, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kristen Prentice, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3112, 

MSC 7808, Bethesda, MD 20892, (301) 496– 

0726, prenticekj@mail.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Arthritis, Connective Tissue and Skin Study 

Section. 

Date: June 8–9, 2022. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Robert Gersch, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20817, (301) 867–5309, robert.gersch@

nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Development—1 

Study Section. 

Date: June 8–9, 2022. 

Time: 10:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Zubaida Saifudeen, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20817, (301) 827–3029, zubaida.saifudeen@

nih.gov. 

Name of Committee: Vascular and 

Hematology Integrated Review Group; 

Atherosclerosis and Vascular Inflammation 

Study Section. 

Date: June 9–10, 2022. 

Time: 9:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Natalia Komissarova, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5207, 

MSC 7846, Bethesda, MD 20892, (301) 435– 

1206, komissar@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Intercellular 

Interactions, Cell Signaling, and Aging. 

Date: June 9, 2022. 

Time: 11:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Thomas Y. Cho, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, Rm. 

5144, MSC 7840, Bethesda, MD 20892, (301) 

402–4179, thomas.cho@nih.gov. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Biobehavioral Regulation, Learning 

and Ethology Study Section. 

Date: June 9–10, 2022. 

Time: 1:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sara Louise Hargrave, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institute of 

Health, 6701 Rockledge Drive, Room 3170, 

Bethesda, MD 20892, (301) 443–7193, 

hargravesl@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–20– 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 91 / Wednesday, May 11, 2022 / Notices 28837 

211: Biobehavioral Regulation, Learning and 

Ethology Research Career Enhancement. 

Date: June 9, 2022. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sara Louise Hargrave, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3170, 

Bethesda, MD 20892, (301) 443–7193, 

hargravesl@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: May 5, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–10061 Filed 5–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute on 

Aging Special Emphasis Panel, June 08, 

2022, 10:00 a.m. to June 09, 2022, 06:00 

p.m., National Institute on Aging, 

Gateway Building, 7201 Wisconsin 

Avenue, Bethesda, MD 20892, which 

was published in the Federal Register 

on May 02, 2022, 309841. 

Dr. Roy wanted to correct the title of 

the meeting to ‘‘Place-based Health 

Inequalities in Mid-life’’. The meeting is 

closed to the public. 

Dated: May 5, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–10059 Filed 5–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK–21–004: 

The Autoantigens and Neoantigens Function 

in the Etiology and Pathophysiology of T1D. 

Date: June 10, 2022. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy Two, 6707 Democracy 

Blvd., Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lan Tian, Ph.D., Scientific 

Review Officer, Review Branch, Division Of 

Extramural Activities, NIDDK, National 

Institutes of Health, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

496–7050, tianl@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: May 5, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–10058 Filed 5–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; Nucleic Acid Sequencing 

Technologies. 

Date: June 1, 2022. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, Suite 300, Bethesda, MD 

20892, (Virtual Meeting). 

Contact Person: Keith McKenney, Ph.D., 

Scientific Review Officer, National Human 

Genome Research Institute, National 

Institutes of Health, 6700B Rockledge Drive, 

Suite 300, Bethesda, MD 20892, (301) 435– 

1580, mckenneyk@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: May 6, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–10123 Filed 5–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; R43/R44: 

Technologies for Assessment of Risk and 

Early Diagnosis of T1D. 

Date: July 11, 2022. 

Time: 1:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy Two, 6707 Democracy 

Blvd., Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lan Tian, Ph.D., Scientific 

Review Officer, Review Branch, Division of 

Extramural Activities, NIDDK, National 

Institutes of Health, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

496–7050, tianl@niddk.nih.gov. 


jspears on DSK121TN23PROD with NOTICES1